National Institute Of Allergy And Infectious Diseases (niaid)

This early-stage study tests two new mRNA vaccines designed to help the immune system fight HIV. About 42 adults with well-controlled HIV will receive the vaccines and then temporarily pause their regular HIV medication under close monitoring. The main goals are to check safety a…

This early-phase study tests whether dasatinib, a drug used for leukemia, can reduce the hidden HIV reservoir in people already on antiretroviral therapy (ART). Fourteen adults with suppressed HIV will take either dasatinib or a placebo daily for 12 weeks, with close monitoring f…

This study tests whether alendronate, a drug used for bone loss, can reduce the hidden HIV reservoir in people already on HIV medication. About 30 participants will receive either alendronate or a placebo, and researchers will measure changes in HIV DNA in the blood. The goal is …

This early-stage study tests whether two lab-made antibodies can safely control HIV when participants pause their regular antiretroviral therapy (ART). The study involves 40 people with HIV who started treatment very early after infection. Researchers will monitor side effects an…

This study looks at whether giving a common steroid (prednisolone) for 7 days can help hospitalized adults with severe lung infections and low oxygen levels. About 3,000 participants will be randomly assigned to receive the steroid or no steroid. The main goal is to see if the st…

This study tests whether adding tezepelumab (an injected drug) to peanut oral immunotherapy (OIT) helps people with peanut allergy tolerate more peanut without symptoms. About 62 people aged 12–55 who react to tiny amounts of peanut will receive either tezepelumab or placebo for …

This study looks at whether children who had a liver transplant before age 7 can safely reduce their anti-rejection medication by half. One hundred children will slowly lower their medicine over 18 months while doctors check their liver health with blood tests and biopsies. The g…

This study tests a 28-day daily pill (rifapentine plus isoniazid) to prevent tuberculosis (TB) in children under 13 years old, including those with HIV. About 144 children will join, split into groups based on HIV status, and be followed for 24 weeks. The goal is to find the best…

This study looks for signs in the body, called biomarkers, that might show if a child will have a reaction to peanut during a feeding test. It will include 500 children aged 1 to 17 who are thought to have a peanut allergy. The goal is to find a way to predict reactions without n…